An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of...
| Published in: | CHEST Vol. 143; no. 5; pp. 1478 - 1480 |
|---|---|
| Main Authors: | , , |
| Format: | case study Journal Article |
| Published: |
American College of Chest Physicians
2013 May
|
| Online Access: | View this record in EBSCOhost |